{"schema_version":"secwatch.filing_event.v1","accession":"0001736730-25-000092","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.281327+00:00","generated_at":"2026-05-16T23:51:17.573575+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CAMP4 Q3 net loss $15.1M, cash $75.3M; advances CMP-002 with up to $100M placement","bullets":["Cash, equivalents, and marketable securities $75.3M at Sept 30, up from $39.1M at June 30.","Private placement initially closed $50M with potential proceeds up to $100M to fund CMP-002.","Initiated GLP toxicology studies for CMP-002; Phase 1/2 trial expected as early as H2 2026.","Strategic decision to pursue partnership for further development of CMP-001 (urea cycle disorders).","Net loss $15.1M for Q3 2025 vs $13.5M for Q3 2024; R&D expenses $9.4M, G&A $4.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001736730-25-000092","json":"https://secwatch.observer/filing/0001736730-25-000092.json","markdown":"https://secwatch.observer/filing/0001736730-25-000092.md","text":"https://secwatch.observer/filing/0001736730-25-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000092/0001736730-25-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000092/camp-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:51:17.573575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}